Canaccord Genuity Raises MedReleaf (LEAF) Price Target to C$30.00

MedReleaf (TSE:LEAF) had its price target lifted by Canaccord Genuity from C$21.50 to C$30.00 in a research report released on Wednesday. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Eight Capital increased their price objective on shares of MedReleaf from C$13.00 to C$20.00 and gave the company a buy rating in a research report on Wednesday, November 15th. Cowen increased their price objective on shares of MedReleaf from C$20.00 to C$36.00 in a research report on Monday, January 8th.

MedReleaf (TSE LEAF) opened at C$20.40 on Wednesday. The firm has a market cap of $2,040.00 and a P/E ratio of 1,020.00. MedReleaf has a 52-week low of C$6.81 and a 52-week high of C$31.25.

In other MedReleaf news, insider Stephen Arbib sold 36,600 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of C$18.01, for a total value of C$659,166.00. Also, insider Olam Ltd. Tikun sold 28,600 shares of the stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of C$25.00, for a total transaction of C$715,000.00. Insiders sold 1,145,100 shares of company stock worth $25,037,466 over the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at

About MedReleaf

MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.

Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with's FREE daily email newsletter.

Leave a Reply